Sort   by:  
 Page size 
MetabolomicsDe Novo Pyrimidine Synthesis Is a Collateral Metabolic Vulnerability in NF2-deficient Mesothelioma

Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumor heterogeneity, including diverse metabolic adaptations. ...

2025-07-07 | MTBLS12461 | MetaboLights
MetabolomicsCYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens and lipid metabolomics to explore the metabo...

2025-02-28 | MTBLS9283 | MetaboLights
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
MetabolomicsPhenomic and multiomic characterisation of microsatellite-stable colorectal cancer reveals novel biology and targets of vulnerability

Integrating data from approximately 2,000 tumour samples, corresponding to ~4,500 platform-specific multiomic sample profiles, and 195,246 single cells/nuclei from diverse in-house and publicly available datasets, single-to-integrated multiomic and clinical phenome data fusion analysis uncovers t...

2026-09-15 | MTBLS15127 | MetaboLights
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
MetabolomicsCrosstalk between S-nitrosylation and glycation defines a novel metabolic vulnerability in liver and renal cancers

Metabolic reprogramming is a defining feature of cancer; however, how it contributes to therapeutic resistance remains incompletely understood. Here we show that loss of aldo-ketoreductase 1A1 (AKR1A1) in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) disrupts terminal glycolytic f...

2026-07-10 | MTBLS15003 | MetaboLights
MetabolomicsCYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens, and lipid metabolomics to explore the metab...

2025-02-28 | MTBLS9288 | MetaboLights
MetabolomicsDEGS1-mTORC1-driven lipid metabolic reprogramming fuels rhabdomyosarcoma progression and unveils a therapeutic vulnerability
These findings establish a mechanistic link between sphingolipid metabolism, mTORC1-mediated regulation of lipophagy, and tumor aggressiveness, highlighting lipid droplet metabolism as a novel and tractable therapeutic target in RMS.
2026-10-02 | MTBLS15896 | MetaboLights
MetabolomicsInduction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer

Tumor-initiating cells (TICs) tend to reside in poorly vascularized regions of tumors and are subjected to nutrient stress. How TICs activate metabolic plasticity for adapting to periods of low nutrient availability, especially during glucose-limiting conditions, has remained unclarified. Here, w...

2025-09-29 | MTBLS8430 | MetaboLights
MetabolomicsAberrant accumulation of cyclin D1 rewires glutamine metabolism via loss of IDH3 generating metabolic vulnerability in ESCC and HNSCC

Excessive cyclin D1 accumulation is a frequent oncogenic event in head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC). Although classically associated with enhanced proliferation and genomic instability, we reveal that cyclin D1 dysregulation induces unexpe...

2026-08-24 | MTBLS13687 | MetaboLights
Sort   by:  
 Page size